SCM Lifescience Co., Ltd.

[Not Yet Scheduled]
SCM Lifescience was established with the vision of developing treatment options for difficult to treat diseases, to provide a new source of hope for patients, and to contribute to the welfare of humanity as a whole using proprietary stem cell isolation technology and stem cell production technology. Through over 15 years of R&D, SCM Lifescience has obtained intellectual property protection for its high-purity stem cell isolation technology – registered patent in Korea in 2008, U.S. in 2010, Japan in 2012, China in 2013, and the EU in 2014; high-purity stem cell manufacturing technology – U.S. patent in 2014; and treatment of graft-versus-host disease – patents from Japan in 2014, U.S. in 2015, and the EU in 2016. Based on these technical breakthroughs, high-purity stem cell therapy shall be provided to treat various immune diseases such as graft-versus-host disease, acute pancreatitis, atopic dermatitis, and type 1 diabetes.
Company Type:
Privately Funded Company
Company HQ State:
Not Provided
Company HQ Country:
Korea - South Korea
Year Founded:
2014
Main Therapeutic Focus:
Lead Product in Development:
stem cell therapeutics
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
CEO
SCM Lifescience Co., Ltd.